Get the Stockscreener App
3.41
3.02%
0.10
Lixte Biotechnology Holdings Inc stock is traded at $3.41, with a volume of 131.02K.
It is up +3.02% in the last 24 hours and down -19.76% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$3.31
Open:
$3.29
24h Volume:
131.02K
Relative Volume:
0.07
Market Cap:
$15.55M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-1.4635
EPS:
-2.33
Net Cash Flow:
$-3.81M
1W Performance:
-5.01%
1M Performance:
-19.76%
6M Performance:
+168.48%
1Y Performance:
+89.44%
1-Day Range:
$3.0801
$3.79
1-Week Range:
$3.0801
$4.04
52-Week Range:
$0.64
$5.14
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
248 ROUTE 25A, EAST SETAUKET
Compare LIXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.41 | 17.42M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Price Action Confirms Reversal in Lixte Biotechnology Holdings Inc. Equity Warrant Trend2025 Biggest Moves & High Return Stock Watch Alerts - classian.co.kr
AI Trend Models Suggest Bounce for Lixte Biotechnology Holdings Inc. Equity WarrantAnalyst Downgrade & Free Risk Controlled Daily Trade Plans - thegnnews.com
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100 - The National Law Review
LIXTE Biotechnology Raises $6.5M, Regains Nasdaq Listing, Appoints New CEO - AInvest
LIXTE Biotechnology Holdings, Inc. Advances Cancer Treatment Strategies with Innovative PP2A Inhibitor LB-100 as Highlighted in Nature Reviews Cancer Editorial - Quiver Quantitative
Price Consolidation Hints at Upcoming Move in Lixte Biotechnology Holdings Inc. Equity WarrantTrade Analysis Report & Scalable Portfolio Growth Methods - beatles.ru
Lixte Biotechnology Raises $6.5M, Appoints New Management - TipRanks
Technical Heatmap Flags Lixte Biotechnology Holdings Inc. Equity Warrant for WatchJuly 2025 Highlights & Community Verified Swing Trade Signals - sundaytimes.kr
LIXTE Biotechnology Holdings Provides Corporate Update - GlobeNewswire
LIXTE Biotechnology Raises $6.5M, Rejoins Nasdaq, Announces Management Changes. - AInvest
Cancer Drug Breakthrough: LIXTE's LB-100 Validated in Nature Study as MD Anderson Reports Survival Gains - Stock Titan
Is Lixte Biotechnology Holdings Inc. stock ready for a breakout2025 Technical Overview & Safe Swing Trade Setups - Newser
What MACD signals say about Lixte Biotechnology Holdings Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - Newser
Using data tools to time your Lixte Biotechnology Holdings Inc. Equity Warrant exit2025 Risk Factors & Safe Capital Allocation Plans - Newser
How to integrate Lixte Biotechnology Holdings Inc. into portfolio analysis toolsSell Signal & Technical Pattern Recognition Alerts - Newser
Published on: 2025-08-16 23:41:24 - Newser
Has Lixte Biotechnology Holdings Inc. found a price floor2025 Market Overview & Weekly High Potential Stock Alerts - Newser
Price momentum metrics for Lixte Biotechnology Holdings Inc. explainedMarket Growth Summary & AI Driven Stock Movement Reports - Newser
Using data filters to optimize entry into Lixte Biotechnology Holdings Inc. Equity Warrant - Newser
Can volume confirm reversal in Lixte Biotechnology Holdings Inc.Weekly Risk Report & Trade Opportunity Analysis Reports - Newser
What Fibonacci levels say about Lixte Biotechnology Holdings Inc. reboundDay Trade & Stepwise Swing Trade Plans - Newser
Chart overlay techniques for tracking Lixte Biotechnology Holdings Inc.2025 Key Highlights & Precise Buy Zone Tips - Newser
How Lixte Biotechnology Holdings Inc. Equity Warrant stock performs during market volatilityJuly 2025 Pullbacks & Weekly Setup with ROI Potential - thegnnews.com
Published on: 2025-08-16 03:16:44 - Newser
Visual trend scoring systems applied to Lixte Biotechnology Holdings Inc. Equity Warrant2025 Retail Activity & Reliable Trade Execution Plans - Newser
Using data models to predict Lixte Biotechnology Holdings Inc. stock movementWeekly Investment Summary & Fast Exit and Entry Strategy Plans - Newser
Can Lixte Biotechnology Holdings Inc. hit a new high this monthAnalyst Upgrade & Smart Allocation Stock Tips - Newser
What MACD and RSI say about Lixte Biotechnology Holdings Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
What the charts say about Lixte Biotechnology Holdings Inc. Equity Warrant todayJuly 2025 Recap & Technical Buy Zone Confirmations - Newser
Tools to assess Lixte Biotechnology Holdings Inc. Equity Warrant’s risk profile2025 Key Highlights & Community Verified Swing Trade Signals - Newser
24/7 Market News: LIXTE Biotech Advances Precision Oncology - GlobeNewswire
Lixte Biotechnology Adopts Cryptocurrency for Treasury Policy - AInvest
Visual analytics tools that track Lixte Biotechnology Holdings Inc. Equity Warrant performanceEarnings Risk Summary & Short-Term Trading Alerts - Newser
LIXTE Biotech Updates Treasury Policy to Include Cryptocurrency Holdings. - AInvest
LIXTE Biotech's LB-100: A Disruptive Oncology Platform with 2025 Catalysts - AInvest
Screener Results Flag Lixte Biotechnology Holdings Inc. as Oversold2025 Stock Rankings & Consistent Profit Trading Strategies - thegnnews.com
LIXTE Biotechnology Holdings Highlights Upcoming Milestones in Cancer Therapy Development - Quiver Quantitative
Identifying reversal signals in Lixte Biotechnology Holdings Inc. Equity WarrantSell Signal & Free Weekly Chart Analysis and Trade Guides - Newser
Lixte Biotechnology Adopts Cryptocurrency in Treasury Policy - TipRanks
LIXTE Biotechnology Holdings Updates Treasury Policy to Allow Cryptocurrency Investments - AInvest
Lixte Biotechnology to allocate up to 25% of treasury to cryptocurrencies. - AInvest
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy - GlobeNewswire
When is the best time to exit Lixte Biotechnology Holdings Inc.Swing Trade & AI Driven Stock Price Forecasts - Newser
Can you recover from losses in Lixte Biotechnology Holdings Inc. Equity Warrant2025 Price Targets & Community Consensus Picks - Newser
Published on: 2025-08-14 16:23:30 - 선데이타임즈
Candlestick signals on Lixte Biotechnology Holdings Inc. stock todayJuly 2025 Pullbacks & Reliable Breakout Forecasts - Newser
Ethereum News Today: Lixte Stock Falls 16% After Bitcoin Treasury Plan Amid Ethereum Strategy Gains - AInvest
Lixte Biotechnology Holdings shares drop 19.07% intraday after announcing up to 25% of funds to be allocated to cryptocurrency investments. - AInvest
LIXTE Biotechnology Announces Strategic Initiative to Acquire Cryptocurrency for Corporate Treasury - SSBCrack
LIXTE Biotechnology adopts cryptocurrency treasury policy By Investing.com - Investing.com Canada
LIXTE Biotech to invest up to 25% in cryptocurrency, diversifying reserves. - AInvest
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):